Shay Shemesh, Chief Development & Operations Officer at Nuvectis Pharma, Inc. (NVCT), bought 300 shares at $16.54 ($5K) on 2022-05-20, disclosed to the SEC on 2022-05-23.
Open-market purchase of $5k NVCT by Chief Development & Operations Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2023-03-17 | $7K | — | Filing → |
| NVCT | BUY | 2022-12-22 | $4K | — | Filing → |
| NVCT | BUY | 2022-11-18 | $2K | — | Filing → |